248 related articles for article (PubMed ID: 34063776)
21. Ultrastructural alterations in endothelial mitochondria are associated with enhanced nitrotyrosine accumulation and progressive reduction of VEGF expression in sequential protocol renal allograft biopsies with calcineurin inhibitor toxicity.
Sharma A; Jain S; Gupta R; Banerjee KG; Guleria S; Agarwal SK; Dinda AK
Transpl Int; 2010 Apr; 23(4):407-16. PubMed ID: 19912591
[TBL] [Abstract][Full Text] [Related]
22. Long-term renal allograft outcome after simultaneous kidney and pancreas transplantation.
Rerolle JP; Thervet E; Anglicheau D; Desgrandchamps F; Nochy D; Janin A; Fornairon S; Passa P; Bedrossian J; Legendre C
Nephrol Dial Transplant; 2002 May; 17(5):905-9. PubMed ID: 11981082
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation.
Fernando M; Peake PW; Endre ZH
Biomark Med; 2014; 8(10):1247-62. PubMed ID: 25525985
[TBL] [Abstract][Full Text] [Related]
24. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
Höcker B; Tönshoff B
Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
[TBL] [Abstract][Full Text] [Related]
25. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
[TBL] [Abstract][Full Text] [Related]
26. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
27. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
Olyaei AJ; de Mattos AM; Bennett WM
Curr Opin Crit Care; 2001 Dec; 7(6):384-9. PubMed ID: 11805539
[TBL] [Abstract][Full Text] [Related]
28. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
Hesselink DA; Bouamar R; van Gelder T
Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
30. The Renal Histopathological Findings in Patients with Renal Allograft Dysfunction: A Retrospective Single Center Study.
Mohammadi Afrakoti M; Nassiri AA; Hakemi MS; Afroughe A; Ganji MR
Iran J Kidney Dis; 2023 May; 17(3):168-173. PubMed ID: 37337801
[TBL] [Abstract][Full Text] [Related]
31. Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.
Gallon L; Mathew JM; Bontha SV; Dumur CI; Dalal P; Nadimpalli L; Maluf DG; Shetty AA; Ildstad ST; Leventhal JR; Mas VR
J Am Soc Nephrol; 2018 Feb; 29(2):423-433. PubMed ID: 29191961
[TBL] [Abstract][Full Text] [Related]
32. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.
Shaffer D; Langone A; Nylander WA; Goral S; Kizilisik AT; Helderman JH
Clin Transplant; 2003; 17 Suppl 9():31-4. PubMed ID: 12795665
[TBL] [Abstract][Full Text] [Related]
33. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
Metalidis C; Lerut E; Naesens M; Kuypers DR
Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
[TBL] [Abstract][Full Text] [Related]
34. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
Danger R; Giral M; Soulillou JP; Brouard S
Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
[TBL] [Abstract][Full Text] [Related]
35. Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation.
Matz M; Lorkowski C; Fabritius K; Durek P; Wu K; Rudolph B; Neumayer HH; Mashreghi MF; Budde K
Transpl Immunol; 2016 Nov; 39():52-59. PubMed ID: 27663089
[TBL] [Abstract][Full Text] [Related]
36. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
37. Causes of late transplant failure in cyclosporine-treated kidney allograft recipients.
Moroni G; Binda V; Quaglini S; Sacchi L; Raffiotta F; Cosa F; Montagnino G; Favi E; Messa P; Ponticelli C
Clin Exp Nephrol; 2019 Aug; 23(8):1076-1086. PubMed ID: 31016431
[TBL] [Abstract][Full Text] [Related]
38. A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation.
Rascio F; Pontrelli P; Accetturo M; Oranger A; Gigante M; Castellano G; Gigante M; Zito A; Zaza G; Lupo A; Ranieri E; Stallone G; Gesualdo L; Grandaliano G
J Pathol; 2015 Sep; 237(1):72-84. PubMed ID: 25925804
[TBL] [Abstract][Full Text] [Related]
39. Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction.
Schauerte C; Hübner A; Rong S; Wang S; Shushakova N; Mengel M; Dettling A; Bang C; Scherf K; Koelling M; Melk A; Haller H; Thum T; Lorenzen JM
Kidney Int; 2017 Sep; 92(3):646-656. PubMed ID: 28396121
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
